Influenza News and Research

Latest Influenza News and Research

NIH responds to criticism over handling of controversial bird flu studies

In a letter dated April 25, Amy Patterson, associate director for science policy in the office of the director of the National Institutes of Health, "has refuted criticism of the way a meeting held to allow a biosecurity advisory group to review controversial bird flu studies was handled," denying "the agenda was crafted to achieve a predetermined outcome," the Canadian Press/Winnipeg Free Press writes.

7 May 2012

BioCryst first quarter revenues increase to $12.2 million

BioCryst Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2012.

7 May 2012

Center for the Promotion of Maternal Health and Infant Development opens

On May 3, 2012, Rady Children's Hospital-San Diego and the UC San Diego School of Medicine launched the Center for the Promotion of Maternal Health and Infant Development.

5 May 2012

One of the controversial avian flu studies published in full finally

After endless debates and controversies on whether two studies that demonstrated how bird flu, also known as avian H5N1 influenza, or avian flu, should be published, one of them has appeared in the latest issue of the journal Nature in its entirety. The two studies aimed for publication in journals Nature and Science show how the bird flu virus could become transmissible from mammal-to-mammal; as humans are mammals, the same would apply to humans.

4 May 2012

Clinical trial to investigate statins in patients with acute severe respiratory failure

Queen's University and NUI Galway and are leading a clinical trial to investigate the possibility that statins, a drug commonly used to combat cholesterol, might help patients with acute severe respiratory failure.

4 May 2012

U.S. to ask university officials how best to implement new DURC policy

"The U.S. government will soon be asking university officials to comment on how best to implement recently released dual use research rules at the university level," according to Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases (NIAID), who spoke Monday at a workshop sponsored by the National Academies in Washington, ScienceInsider reports.

3 May 2012

Flu paper publication amidst threats of bioterrorism raises need for better rules of censorship

According to the editor of the scientific journal Nature, Dr Philip Campbell current procedures to assess and censor medical research potentially of use to terrorists need to be improved. He was speaking about the recent controversy regarding the bird flu virus H5N1 study. The study was initially stopped from publication fearing risk of bioterrorism. He was speaking to BBC News.

2 May 2012

Inovio's SynCon vaccine for cervical dysplasias and cancers granted U.S. patent

Inovio Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,168,769, covering Inovio's SynCon vaccine for cervical dysplasias and cancers caused by human papillomavirus (HPV).

2 May 2012

Sanofi Pasteur announces new quadrivalent influenza vaccine Phase III pediatric data

Sanofi Pasteur, the vaccines division of Sanofi, announced today new Phase III data for its investigational quadrivalent influenza vaccine (QIV) in children 6 months through 8 years of age.

2 May 2012

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.

2 May 2012

'Mandatory oversight' of potentially dangerous biological research will be necessary

"In the sobering annals of disaster prevention, genetic manipulation of the H5N1 influenza virus is looming as a seminal case," John Steinbruner, director of the Center for International Security Studies at the University of Maryland, writes in an opinion piece in The Hill's "Congress Blog," noting that two "laboratory experiments have rendered the highly virulent avian strain transmissible among ferrets, strongly suggesting that it would be transmissible among humans as well."

2 May 2012

Pfizer receives FDA approval for Elelyso to treat Type 1 Gaucher disease

The U.S. Food and Drug Administration today approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder.

2 May 2012

Some public health advocates disagree with Indian government's decision to roll out pentavalent vaccines, IPS reports

"Ignoring widespread concern over the safety, efficacy and cost of pentavalent vaccines" -- which provide protection against diphtheria, pertussis, tetanus, hepatitis B and haemophilus influenza type b (Hib) -- "India's central health ministry has, this month, approved inclusion of the prophylactic cocktail in the universal immunization program in seven of its provinces," Inter Press Service reports.

30 Apr 2012

Dutch government grants export license allowing publication of controversial H5N1 study

"The Dutch government has agreed to grant an export license to allow Ron Fouchier, a virologist at the Erasmus Medical University in Rotterdam, to publish his work on H5N1 avian influenza in Science," Nature's "News Blog" reports (Owens, 4/27). "

30 Apr 2012

Senate committee questions federal officials about dual-use research of concern procedures

"Spurred by events surrounding two controversial H5N1 transmission studies, a U.S. Senate committee [on Thursday] questioned federal officials whose agencies have a stake in dual-use research of concern (DURC) about the procedures they use to spot possible bioterror threats," CIDRAP News reports.

27 Apr 2012

U.S. government must be prepared to handle dual use research of concern

"This week, a Senate panel is investigating biological security in the wake of" controversial "potentially dangerous research" on H5N1 avian influenza, "with good reason," Rep. Jim Sensenbrenner (R-Wisc.) writes in a Washington Times opinion piece.

26 Apr 2012

Text-message intervention may help boost flu vaccination rates in children

Text message reminders to parents about flu vaccinations may help boost the number of children vaccinated, according to researchers at Columbia University Medical Center and NewYork-Presbyterian Hospital. Full study findings are reported in the April 25 issue of the Journal of the American Medical Association.

26 Apr 2012

Pig mucus effective at blocking viruses associated with cervical and oral cancer

Scientists are reporting that the mucus lining the stomachs of pigs could be a long-sought, abundant source of "mucins" being considered for use as broad-spectrum anti-viral agents to supplement baby formula and for use in personal hygiene and other consumer products to protect against a range of viral infections. Their study appears in ACS' journal Biomacromolecules.

26 Apr 2012

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.

26 Apr 2012

Rep. Sensenbrenner sends second letter inquiring about U.S. government's review of controversial H5N1 studies

"A senior Republican in the U.S. House of Representatives is asking more questions about how the U.S. government reviewed two controversial H5N1 avian influenza studies, and how it wrote a new policy for reviewing taxpayer-funded studies that might be used for good and evil," ScienceInsider reports.

25 Apr 2012

Influenza News and Research

Latest Influenza News and Research

NIH responds to criticism over handling of controversial bird flu studies

BioCryst first quarter revenues increase to $12.2 million

Center for the Promotion of Maternal Health and Infant Development opens

One of the controversial avian flu studies published in full finally

Clinical trial to investigate statins in patients with acute severe respiratory failure

U.S. to ask university officials how best to implement new DURC policy

Flu paper publication amidst threats of bioterrorism raises need for better rules of censorship

Inovio's SynCon vaccine for cervical dysplasias and cancers granted U.S. patent

Sanofi Pasteur announces new quadrivalent influenza vaccine Phase III pediatric data

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

'Mandatory oversight' of potentially dangerous biological research will be necessary

Pfizer receives FDA approval for Elelyso to treat Type 1 Gaucher disease

Some public health advocates disagree with Indian government's decision to roll out pentavalent vaccines, IPS reports

Dutch government grants export license allowing publication of controversial H5N1 study

Senate committee questions federal officials about dual-use research of concern procedures

U.S. government must be prepared to handle dual use research of concern

Text-message intervention may help boost flu vaccination rates in children

Pig mucus effective at blocking viruses associated with cervical and oral cancer

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

Rep. Sensenbrenner sends second letter inquiring about U.S. government's review of controversial H5N1 studies

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Influenza News and Research

Latest Influenza News and Research

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Newsletters you may be interested in